1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Insight Pharma Reports Announces New Trends in Preventive and Therapeutic Vaccines Report

New Trends in Preventive and Therapeutic Vaccines: R&D Activities and Commercial Prospects

 
 
InsightPharmaReports com
InsightPharmaReports com
PRLog - Oct. 25, 2011 - NEEDHAM, MASS.  Cambridge Healthtech Institute’s Insight Pharma Reports announces the New Trends in Preventive and Therapeutic Vaccines Report, authored by Herman AM Mucke, PhD.

This report provides an analytical snapshot of the current state of the vaccine industry, its development efforts, and an outlook to 2020, examining:

•Vaccines for prevention of infectious diseases including hepatitis, influenza, polio, rabies, tropical viruses, and HIV
•Therapeutic vaccines that target HIV, HCV, asthma and allergy, type 1 diabetes, multiple sclerosis, psoriasis, arthritis, atherosclerosis, transplant rejection, Alzheimer’s disease, periodontitis, substance abuse, obesity, cachexia, and age-related macular degeneration
•Therapeutic cancer vaccines, including all cancer vaccines currently known to be in Phase III clinical trials and an overview of products that are in Phase I or II
•Perspectives for vaccine development, the direction the markets are likely to take to 2020, and estimates for market growth
•Results of a four-part survey offering unique insights into industry sentiment concerning vaccine development to 2020
•Advances in vaccine design, formulation, and delivery
•Company profiles of large pharmaceutical players in the vaccine business and small vaccine specialist companies



New Trends in Preventive and Therapeutic Vaccines: R&D Activities and Commercial Prospects begins by dealing with the major task of vaccines: prevention of infectious diseases.  A thorough overview of vaccine-preventable diseases is given, with a special focus on human immunodeficiency virus (HIV), hepatitis C, and influenza. We use the case of a potential HIV vaccine for an analysis of how the first vaccine for a previously “unvaccinable” major infectious disease could fare, on the market and in terms of epidemiological impact, assuming several scenarios. The major corporate players on the market, and vaccine specialist companies including those developing or selling vaccines for “weaponized” biological agents such as anthrax, are reviewed as are the international organizations and the charities, which play the dominant role in making standard vaccines accessible to the developing nations. Attention is given to emerging tropical viral diseases (such as Dengue and West Nile virus), which are increasingly spreading to the temperate zones of the globe. A special section is devoted to the challenge of tropical parasitic diseases. Opposition to vaccination is also discussed.

We then turn to therapeutic vaccines that target chronic infectious diseases, but also non-infectious conditions with massive immune system involvement. A special section addresses efforts to develop therapeutic vaccines for conditions that most people would not consider targets for this type of intervention. Therapeutic cancer vaccines are covered in a separate chapter. This part of the report reviews the paradigms of active immune intervention in cancer and the problems it faces, as well as discusses cancer vaccines in clinical development. Standardized cancer vaccines, which work by harnessing the patient’s immune system, should offer a completely new therapeutic angle. Most importantly, they would be best suited to prevent tumor recurrence once a complete remission has been achieved by initial therapy—which would open an entirely new perspective for cancer survivors, and a completely new market as well.

Insight Pharma Reports conducted a four-part online survey in late September/early October 2011, which covered preventive vaccines for infectious diseases in general, influenza vaccines, HIV and HCV vaccines, and cancer vaccines. Analyses of the responses can be found throughout this report.

For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com

About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  http://www.InsightPharmaReports.com

# # #

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.

Photo:
http://www.prlog.org/11707054/1

--- End ---

Click to Share

Contact Email:
***@healthtech.com Email Verified
Source:Insight Pharma Reports
Phone:781-972-1347
Zip:02494
City/Town:Needham - Massachusetts - United States
Industry:Biotech, Health, Science
Tags:vaccine, vaccination, hepatitis, influenza, rabies, hiv, life sciences, pharma, big pharma, biotech, market report, ipr
Last Updated:Oct 25, 2011
Shortcut:prlog.org/11707054
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share